Trials / Terminated
TerminatedNCT04311710
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ipilimumab | Specified Dose on Specified Days |
| DRUG | nivolumab | Specified Dose on Specified Days |
| DRUG | ENHANZE (rHuPH20) | Specified Dose on Specified Days |
| DRUG | nivolumab | Specified Dose on Specified Days |
Timeline
- Start date
- 2020-06-25
- Primary completion
- 2021-01-14
- Completion
- 2023-01-18
- First posted
- 2020-03-17
- Last updated
- 2023-02-24
Locations
6 sites across 3 countries: United States, Italy, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04311710. Inclusion in this directory is not an endorsement.